Drug–drug interactions in patients receiving hematopoietic stem cell transplantation
- 27 November 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 15 (1) , 49-59
Abstract
Introduction: Recipients of hematopoietic stem cell transplantation (HSCT) are exposed to numerous drugs in both pre- and post-transplantation period, which creates an opportunity for drug-drug interactions (DDIs); if clinically relevant DDIs happen, the risk of adverse treatment outcomes is increased. Areas covered: This review is focused on DDIs in recipients of HSCT that were observed and published as clinical trials, case series or case reports. Relevant publications were found by the systematic search of the following online databases: MEDLINE, SCOPUS, EBSCO, and SCINDEX. Expert opinion: The most important DDIs involve cytostatic or immunosuppressant drug on one side, and antimicrobial drugs on the other. The majority of clinically relevant interactions have pharmacokinetic character, involving drug metabolizing enzymes in the liver. Antifungal azoles inhibit metabolism of many cytostatic and immunosuppressant drugs at cytochromes and increase their plasma concentrations. Macrolide antibiotics and fluoroqunolones should be avoided in HSCT recipients, as they have much larger potential for drug-drug interactions than other antibiotic groups. HSCT recipients increasingly receive new immunomodulating drugs, and further observational studies are needed to reveal unsuspected drug-drug interactions with clinical relevance.Keywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (175007)
This publication has 84 references indexed in Scilit:
- Elevation of blood ciclosporin levels by voriconazole leading to leukoencephalopathyJournal of Pharmacology and Pharmacotherapeutics, 2013
- Effect of Posaconazole on Cyclosporine Blood Levels and Dose Adjustment in Allogeneic Blood and Marrow Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2012
- Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantationInt. Journal of Clinical Pharmacology and Therapeutics, 2012
- Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azolesBone Marrow Transplantation, 2012
- Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCTBone Marrow Transplantation, 2011
- Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infectionsDrug, Healthcare and Patient Safety, 2010
- Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2006
- Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic Hematopoietic Stem Cell Transplant RecipientsTransplantation and Cellular Therapy, 2006
- Effects of the Antifungal Agents on Oxidative Drug MetabolismClinical Pharmacokinetics, 2000
- Possible Interaction between Phenobarbital, Carbamazepine and ItraconazoleDrug Safety, 1993